Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD4 | Q15561 | 15/20 | 0.44 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.40 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.40 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21887783 | 0.82 | TEAD4 (0.49) | TEAD4TEAD1TEAD2TEAD3KDM4E | |
| SCHEMBL21887350 | 0.82 | FFAR1 (0.51) | TEAD4TEAD1TEAD2TEAD3KDM4E | |
| SCHEMBL20624582 | 0.79 | TEAD4 (0.46) | TEAD4TEAD1TEAD2TEAD3KDM4E | |
| SCHEMBL20601842 | 0.78 | GPR84 (0.55) | TEAD4TEAD1TEAD2TEAD3KDM4E | |
| SCHEMBL20601510 | 0.76 | TEAD4 (0.47) | TEAD4TEAD1TEAD2TEAD3KMT2A | |
| SCHEMBL20624680 | 0.75 | HDAC3 (0.47) | TEAD4TEAD1TEAD2TEAD3 | |
| SCHEMBL20624608 | 0.75 | HDAC3 (0.47) | TEAD4TEAD1TEAD2TEAD3 | |
| SCHEMBL20624406 | 0.75 | HDAC3 (0.47) | TEAD4TEAD1TEAD2TEAD3 | |
| SCHEMBL20601552 | 0.75 | HDAC3 (0.47) | TEAD4TEAD1TEAD2TEAD3 | |
| SCHEMBL20601560 | 0.75 | HDAC3 (0.47) | TEAD4TEAD1TEAD2TEAD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180486-B2 | Indolylkojyl methane analogues, process of preparation thereof and use as inhibitor of cancer cells invasion and metastasis | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-11-23 | — | — | US | disclosed |
| US-20200115365-A1 | INDOLYLKOJYL METHANE ANALOGUES, PROCESS OF PREPARATION THEREOF AND USE AS INHIBITOR OF CANCER CELLS INVASION AND METASTASIS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115365-A1 | INDOLYLKOJYL METHANE ANALOGUES, PROCESS OF PREPARATION THEREOF AND USE AS INHIBITOR OF CANCER CELLS INVASION AND METASTASIS | MIF, CYP11B1, CCNI | TEAD4 1017/4885TEAD1 1189/4885TEAD2 1351/4885 |
| US-11180486-B2 | Indolylkojyl methane analogues, process of preparation thereof and use as inhibitor of cancer cells invasion and metastasis | MIF, CYP11B1, MKI67 | TEAD4 1059/4885TEAD1 1211/4885TEAD2 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.